N/A
N=48
Gingival Bleeding and Von Willebrand Disease Typ 2 and 3
Gingival Bleeding · Von Willebrand Diseases
Bottom Line
View on ClinicalTrials.gov: NCT03078595 ↗Enrolled (actual)
48
Serious AEs
0.0%
Results posted
Feb 2020
Primary outcome: Primary: Bleeding on Probing (BOP) — 14.5; 12.3 percentage of sites
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Goethe University
- Primary completion
- Apr 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Bleeding on Probing (BOP) |
14.5; 12.3 | — |
| SECONDARY Gingival Bleeding Index (GBI) |
10.5; 8.8 | — |
Summary
Von Willebrand disease (VWD) is the most common inherent bleeding disorder resulting in prolonged bleeding time. Gingival bleeding is a frequently reported symptom of VWD. However, gingival bleeding is also known as a leading symptom of plaque-induced gingivitis and untreated periodontal disease. Gingival bleeding in VWD patients may be triggered by gingival inflammation and not a genuine symptom. Thus, this study evaluates whether type 2 and 3 VWD determines an increased susceptibility to gingival bleeding in response to the oral biofilm.
Eligibility Criteria
Inclusion Criteria von Willebrand Patients:
- 18 - 80 years old
- no other bleeding disorder except 2 and 3 von Willebrand disease
Inclusion Criteria healthy controls:
- no bleeding disorder
- no anticoagulative medication
Exclusion Criteria von Willebrand Patients:
- requirement of systemic antibiotics for measures that may cause transitory bacteraemia
Exclusion Criteria healthy controls:
- bleeding disorder
Data sourced from ClinicalTrials.gov (NCT03078595). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.